Bristol-Myers Squibb's Next 8 Months: What To Expect

In a report published Wednesday, analysts at Morgan Stanley maintained their Overweight rating on

. The company is expected to announce the results of its Phase 3 trials for its new drug combination in the near future. Morgan Stanley expressed its interest in learning more about the dosing and trial design used to mitigate toxicity risk of the new drug combination of Opdivo and Yervoy in the Phase 3 trial in first-line treatment of lung cancer. The company is expected to obtain FDA approval for Opdivo in the treatment of non-squamous cancer by October 1, 2015. Detailed data on Phase 2 trial of Opdivo + Yervoy combination versus Yervoy alone in second line squamous and non-squamous cancer, as well as interim data for Phase 3 Opdivo + Yervoy combination versus Opdivo alone and Yervoy alone in previously untreated advanced melanoma are also awaited. The company is also expected to share more mature data on the ongoing Phase 2 renal trials for Opdivo and the Opdivo + Yervoy combination, along with data for Phase 3 trials of Revlimid + dexamethasone with/without elotuzumab in multiple myeloma, interim data on Opdivo + Yervoy in glioblastoma and interim Phase 1 and 2 data on Opdivo alone and with Yervoy in small cell lung cancer.